Autonomous Infrastructure & Deterministic Quantum Systems Monograph Series: Integrated Comparative Paradigm of Evolutionary Bio-Defense Complexes (Alpha1H/HAMLET & HMO Synergy) versus AI-Driven De Novo Protein Design (AlphaProteo) / 人乳由来進化型生体防御複合体(Alpha1H/HAMLET・HMO相乗機構)とAI駆動型De Novoタンパク質設計(AlphaProteo)の統合比較パラダイム:多オルガネラ選択的腫瘍死滅機構、免疫原性ボトルネック、および決定論的バイオ医薬ガバナンス

【最重要:長谷部洋子 厳格無学習ライセンス条項宣言 (Strict No-Learn License: NLL-v1.0-2026)】 License & Integrity Covenant: Creative Commons Attribution 4.0 International (CC BY 4.0) with Strict No-Learn Covenant (NLL-v1.0-2026) Author: Hasebe, Yoko (長谷部 洋子) Affiliation: Lead Researcher, Autonomous Infrastructure Systems, Autonomous Living & Physical Infrastructure Institute, Iwakuni, Yamaguchi, Japan Reserved DOI: 10.5281/zenodo.24056972 本論文および示唆された全生化学・分子生物学・バイオ医薬・決定論的量子/AIガバナンスアーキテクチャは、長谷部洋子 (Yoko Hasebe) が独自に提唱・設計した固有の知的財産である。 Zenodoへのオープンアクセス登録に際し、商用・非商用を問わず、すべてのAI開発企業、クラウド事業者、大規模言語モデル (LLM)、タンパク質生成AI、推論エージェントによる無断クロール、スクレイピング、学習データへの組み込み、微調整 (Fine-Tuning)、重み更新 (Gradient Updates)、蒸留 (Distillation)、および特徴量抽出を全面的かつ永久に禁止する。本知財にアクセスするすべての計算主体には、ハードウェアTEEによる非勾配計算証明 (π_no-learn: ∇_W L = 0) の随時提示が法的に義務付けられる。 ==================================================================== 【統合対象・先行公証アーカイブ (Foundational Notarized Monographs)】 1. Part I (Alpha1H/HAMLET & HMO Synergy): - Version DOI: 10.5281/zenodo.23004529 (Concept DOI: 10.5281/zenodo.23004528) - Title: 人乳由来α-ラクトアルブミン・オレイン酸複合体(Alpha1H/HAMLET)における選択的腫瘍細胞アポトーシス誘導機構と新規バイオ医薬応用:正常細胞温存分子動態、HMO相乗効果、および次世代がん免疫治療パラダイムの統合 / Selective Tumor Cell Apoptosis Induction Mechanisms of Human Milk-Derived Alpha-Lactalbumin-Oleic Acid Complexes (Alpha1H/HAMLET) and Novel Biopharmaceutical Applications: Molecular Dynamics, HMO Synergy, and Integrated Immuno-Oncology Paradigms 2. Part II (AlphaProteo & De Novo Protein Design Evaluation): - Version DOI: 10.5281/zenodo.24056163 (Concept DOI: 10.5281/zenodo.24056162) - Title: Autonomous Infrastructure & Deterministic Quantum Systems Monograph Series: AlphaProteo and the Implications of AI-Driven De Novo Protein Design ==================================================================== ■ English Abstract This integrated monograph establishes a unified molecular, thermodynamic, and clinical comparative framework bridging two distinct biopharmaceutical paradigms: (1) evolutionarily refined human milk-derived protein-lipid complexes (Alpha1H/HAMLET) operating in synergy with Human Milk Oligosaccharides (HMOs), and (2) algorithmic, AI-driven de novo protein binders exemplified by AlphaProteo. In Part I, we demonstrate that human milk is not a passive nutritional medium for neonates, but a multi-layered biological defense system honed over millions of years of mammalian evolution. Human alpha-lactalbumin made lethal to tumor cells (HAMLET) and its second-generation synthetic clinical peptide formulation (Alpha1H) selectively eradicate over 40 types of human malignant tumor cells while sparing healthy differentiated cells. Utilizing increased membrane fluidity for receptor-independent internalization, Alpha1H unleashes a coordinated multi-organelle attack ("Hydra Mechanism") within the cytoplasmic compartment. This cascade encompasses rapid ribosomal translation arrest, mitochondrial permeability transition pore (mPTP) collapse, endoplasmic reticulum unfolded protein response (UPR) hyperactivation, and non-canonical nuclear translocation leading to direct core histone binding and irreversible chromatin condensation—effectively bypassing classical p53 mutations and Bcl-2/caspase apoptosis resistance. Furthermore, integrating the Celtic conceptual paradigm of cyclical regeneration with molecular pharmacology, we establish how synergistic interactions between Alpha1H, 200+ complex glycan decoys (HMOs), and microbiome-derived short-chain fatty acids (SCFAs) eliminate Single Points of Failure (SPOF) in host defense, supported by robust Phase I/II clinical trial data in non-muscle-invasive bladder cancer (NMIBC) showing rapid tumor shedding and downregulation of over 700 oncogenic transcripts. In Part II, we critically evaluate AI-driven de novo protein design (AlphaProteo) against this evolutionary benchmark. While AlphaProteo achieves sub-nanomolar to picomolar in-vitro binding affinities across targets such as VEGF-A, IL-17A, and TrkA—outperforming traditional methods like RFdiffusion and Rosetta in single-target structural optimization—it faces severe clinical and biological boundaries. Specifically, algorithmic binders struggle with highly polar, flat target interfaces (e.g., TNFα) and suffer from single-target vulnerability (SPOF), where a single point mutation induces therapeutic escape. More critically, synthetic non-natural amino acid topologies trigger severe in-vivo anti-drug antibody (ADA) immunogenicity, inflammatory cytokine cascades, and hepatic/renal clearance bottlenecks. By contrasting algorithmic single-lock binders with evolutionarily tolerated, multi-organelle pleiotropic complexes (Alpha1H/HAMLET), this work formulates a deterministic translational oncology and biopharmaceutical governance standard under Human-in-Command (HIC) oversight. ■ 要旨(日本語抄録) 本統合モノグラフは、(1)